Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Interleukin Genetics, Inc (NasdaqSC:ILGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | SEC | Msgs | Insider | Financials | Reports
Location
135 Beaver Street, 20nd Floor
Walthan, MA 02452
Phone: (781) 398-0700
Fax: (781) 398-0720
Employees (last reported count): 13
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Healthcare Facilities
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 35%
·Institutional: 16% (25% of float)
(16 institutions)
·Net Inst. Buying: 116.0K shares (+3.18%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Interleukin Genetics, Inc. is a functional genomics company focused on personalized medicine. The Company has a portfolio of patents covering the genetics of many common diseases and conditions, including cardiovascular diseases, osteoporosis, complications of diabetes, restenosis and periodontal disease. Its first genetic test, PST, a test predictive of risk for periodontal disease, is currently marketed in the United States, Europe and Israel. Other products under development include tests predictive of risk for osteoporosis, coronary artery disease, complications of diabetes and restenosis. The Company has also developed and licensed medical research tools, including BioFusion, to pharmaceutical and biotech companies. BioFusion is a computer modeling system that allows useful information to be derived from rapidly increasing databases of gene expression being generated in companies and academic centers worldwide.
More from Market Guide: Expanded Business Description

Financial Summary
Interleukin Genetics, Inc. provides genetic susceptibility testing services for common and treatable diseases. The Company focuses on four diseases; periodontitis, osteoporosis, coronary artery and diabetic retinopathy. For the six months ended 6/30/01, revenues fell 5% to $159 thousand. Net loss decreased 10% to $2.3 million. Revenues reflect a change in strategy for marketing, distributing and processing PST. Lower loss benefitted from decreased administrative costs.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Philip Reilly, M.D., 53
Chairman and CEO
$307K$74K
Kenneth Kornman, Ph.D., 53
Pres, CSO
368K--  
Fenel Eloi, 42
COO, Chief Financial Officer
106K--  
Paul Martha, Jr., M.D., 47
CMO
23K--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqSC:ILGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 6-Apr-2001
$1.125
Recent Price$2.10 
52-Week High
on 14-Sep-2000
$6.50 
Beta2.08 
Daily Volume (3-month avg)23.6K
Daily Volume (10-day avg)14.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y]
52-Week Change-58.0%
52-Week Change
relative to S&P500
-43.7%
Share-Related Items
Market Capitalization$45.0M
Shares Outstanding21.4M
Float13.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.27 
Earnings (ttm)-$0.24 
Earnings (mrq)-$0.05 
Sales (ttm)$0.01 
Cash (mrq)$0.30 
Valuation Ratios
Price/Book (mrq)7.91 
Price/EarningsN/A 
Price/Sales (ttm)166.60 
Income Statements
Sales (ttm)$247.0K
EBITDA (ttm)-$4.87M
Income available to common (ttm)-$4.73M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-77.75%
Return on Equity (ttm)-94.79%
Financial Strength
Current Ratio (mrq)6.49 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$6.36M
Short Interest
As of 8-Aug-2001
Shares Short8,000 
Percent of Float0.1%
Shares Short
(Prior Month)
7,000 
Short Ratio0.47 
Daily Volume17.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.